ALK and MYCN: when Two Oncogenes Are Better Than One

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2012 Mar 24

PMID 22439928

Citations 3

Authors

Zhihui Liu

Carol J Thiele

Affiliations

Soon will be listed here.

Abstract

Mutations of ALK are frequently observed in MYCN-amplified neuroblastomas and correlate with poor clinical outcome, but how these oncogenes cooperate in neuroblastoma development remains unclear. In this issue of Cancer Cell, Zhu et al. describe a mechanism by which ALK and MYCN synergistically induce neuroblastoma in the zebrafish model system.

Citing Articles

Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma.

Bate-Eya L, Albayrak G, Carr S, Shrestha A, Kanapin A, Samsonova A Mol Oncol. 2024; 19(3):741-763.

PMID: 39021294 PMC: 11887678. DOI: 10.1002/1878-0261.13702.

An overview of neuroblastoma cell lineage phenotypes and models.

Campos Cogo S, Gradowski Farias da Costa do Nascimento T, de Almeida Brehm Pinhatti F, de Franca Junior N, Santos Rodrigues B, Cavalli L Exp Biol Med (Maywood). 2020; 245(18):1637-1647.

PMID: 32787463 PMC: 7802384. DOI: 10.1177/1535370220949237.

Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.

Javanmardi N, Fransson S, Djos A, Sjoberg R, Nilsson S, Truve K Sci Rep. 2019; 9(1):2199.

PMID: 30778092 PMC: 6379392. DOI: 10.1038/s41598-018-37240-z.

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Hallberg B, Palmer R Nat Rev Cancer. 2013; 13(10):685-700.

PMID: 24060861 DOI: 10.1038/nrc3580.

References

Schonherr C, Ruuth K, Kamaraj S, Wang C, Yang H, Combaret V . Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene. 2012; 31(50):5193-200. DOI: 10.1038/onc.2012.12. View

Hogarty M, Maris J . PI3King on MYCN to improve neuroblastoma therapeutics. Cancer Cell. 2012; 21(2):145-7. DOI: 10.1016/j.ccr.2012.01.018. View

Mertz J, Conery A, Bryant B, Sandy P, Balasubramanian S, Mele D . Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011; 108(40):16669-74. PMC: 3189078. DOI: 10.1073/pnas.1108190108. View

Zhu S, Lee J, Guo F, Shin J, Perez-Atayde A, Kutok J . Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012; 21(3):362-73. PMC: 3315700. DOI: 10.1016/j.ccr.2012.02.010. View

Wang C, Liu Z, Woo C, Li Z, Wang L, Wei J . EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res. 2011; 72(1):315-24. PMC: 3487161. DOI: 10.1158/0008-5472.CAN-11-0961. View